NCT03472287View on ClinicalTrials.gov

To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 18, 2018

Primary Completion Date

January 31, 2019

Study Completion Date

February 14, 2019

Conditions
Epidermolysis Bullosa (EB)Epidermolysis Bullosa SimplexDystrophic Epidermolysis BullosaJunctional Epidermolysis Bullosa
Interventions
DRUG

Diacerein 1% Ointment

Diacerein 1% Ointment administered topically

Trial Locations (3)

27599

UNC Dermatology, Chapel Hill

60654

Northwestern University Medical Center, Chicago

94304

Stanford School of Medicine, Palo Alto

Sponsors
All Listed Sponsors
lead

Castle Creek Pharmaceuticals, LLC

INDUSTRY